Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eisai Research Institute Opens Andover Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Eisai Research Institute Opens Andover Facility

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eisai Research Institute of Boston, Inc., a pharmaceutical R&D subsidiary of Tokyo-based Eisai Co., Ltd., has opened a new facility at its site in Andover, MA. The 150,000-sq.-ft. structure will consolidate basic discovery research operations and provide for future growth.

The $65 million facility will be devoted to discovery research using natural products-based synthetic organic chemistry and target-oriented biology to identify and develop drug compounds. Part of Eisai’s business plan, the “Dramatic Leap Plan,” the state-of-the-art labs and office space will provide increased opportunity for scientific discovery and compound selection.

Eisai Research currently has two compounds in Phase III trials globally, one for the treatment of severe sepsis and the other for cancer. Additional compounds discovered at Eisai Research Institute are in preclinical and clinical development for the treatment of cancer and other diseases.

“We are delighted to commemorate today’s dedication,” said Michael Lewis, president, Eisai Research Institute. “We are confident that the environment we have created will actively promote the atmosphere of collaboration and teamwork that has been a critical source of Eisai’s cutting edge science.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics